WC
DMIIR

Wealthspring Capital’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Wealthspring Capital’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32K Sell
400,440
-2,230
-0.6% -$191 0.01% 183
2026
Q1 		$32.2K Sell
402,670
-6,280
-2% -$713 0.01% 172
2025
Q4 		$57.3K Buy
+408,950
New +$58.4K 0.01% 144

Other funds holding DMIIR

CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MCS
Mercuria Capital Strategies Houston, Texas $163M AUM 258.7% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Wealthspring Capital's DMIIR Position: Q2 2026 in Review

Wealthspring Capital reduced its Drugs Made In America Acquisition II Corp Right (DMIIR) stake by 0.55% in Q2 2026, selling an estimated $191 and leaving 400,440 shares worth $32K. The position accounts for 0.01% of the portfolio, ranked #183.

Wealthspring Capital first reported a position in DMIIR in Q4 2025 and has held it in 3 quarters since. The position peaked at $57.3K in Q4 2025. 8 funds tracked by Wall St. Rank hold DMIIR as of Q2 2026.

  • Wealthspring Capital held 400,440 shares of Drugs Made In America Acquisition II Corp Right worth $32K as of Q2 2026.
  • Wealthspring Capital sold 2,230 Drugs Made In America Acquisition II Corp Right shares in Q2 2026, an estimated $191.
  • Drugs Made In America Acquisition II Corp Right made up 0.01% of Wealthspring Capital's portfolio in Q2 2026, its #183 holding.
  • Wealthspring Capital first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 3 quarters since.
  • Wealthspring Capital's Drugs Made In America Acquisition II Corp Right position peaked at $57.3K in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q2 2026.

Based on Wealthspring Capital's 13F filing for Q2 2026, filed 15 Jul 2026.